Want to see LUCD full AI Analyst Report?
LUCD Stock Chart & Stats
$0.91
<$0.01(0.26%)
At close: 4:00 PM EDT
$0.91
<$0.01(0.26%)
Day’s Range― - ―
52-Week Range$0.86 - $1.63
Previous CloseN/A
Volume689.08K
Average Volume (3M)1.86M
Market Cap
$195.99M
Enterprise Value$187.45
Total Cash (Recent Filing)$33.40M
Total Debt (Recent Filing)$24.91M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding203,243,970
10 Day Avg. Volume1,959,284
30 Day Avg. Volume1,861,430
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.16
Price to Sales (P/S)23.61
P/FCF Ratio-2.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.19Price Target Upside360.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$7.38M
Bulls Say, Bears Say
Bulls Say
Growing Test Volume And RevenueIncreasing test volume and revenue show that EsoGuard is gaining commercial adoption. Continued expansion in clinical ordering could improve operating leverage over time, provided Lucid converts billable activity into collected revenue.
Expanding Payer AccessPositive coverage policies reduce a major adoption barrier for clinicians and patients. Broader health-plan acceptance could establish reimbursement precedent, expand the addressable market, and support more durable testing growth beyond individual contracts.
Potentially Attractive Test EconomicsLow direct processing and collection costs relative to potential reimbursement create substantial gross-margin potential once utilization and collections scale. The cost-effectiveness model may further support payer adoption and strengthen long-term unit economics.
Bears Say
Severe Operating LossesLucid has not yet demonstrated positive gross margin or operating leverage despite revenue growth. Sustained losses indicate that commercial expansion must accelerate materially before the business can become self-funding or support a stable long-term earnings profile.
Reimbursement And Collection RiskLow conversion from billed tests to recognized revenue exposes Lucid to payer policy, authorization, documentation, and collection risk. This can delay cash generation, make revenue unpredictable, and limit the benefit of higher testing volumes until coverage improves.
High Cash Burn And LeverageHeavy cash consumption relative to current revenue creates ongoing financing dependence. The costly secured convertible debt reduces flexibility, while future capital raises or conversion could increase dilution and constrain investment if reimbursement progress is slower than expected.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.86 and its highest was $1.63 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Lucid Diagnostics’s market cap is $195.99M.
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Aug 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.057 by -$0.003.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -0.05.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 203,243,970 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.057. Following the earnings report the stock price went down -2.033%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.19 (360.16% Upside)
$4.19 (360.16% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $245.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.71%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial and market-access progress—most notably the first LBM coverage policy from Concert, encouraging preliminary HEOR results, targeted test volumes within guidance, and a successful $16.8M equity raise—while simultaneously highlighting persistent reimbursement and collection challenges (pending Medicare LCD, low near-term revenue capture of billable tests, adjudication/denial rates), a sustained quarterly cash burn (~$11.3M), and financing obligations. Achievements on coverage, HEOR, and health system engagement materially de‑risk the commercial pathway over time, but near-term financial performance remains constrained by reimbursement timing and claim collection dynamics.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$4.19
▲(360.16% Upside)
Technical Analysis
Ownership Overview
5.36% Insiders
3.77% Mutual Funds
11.35% Other Institutional Investors
72.99% Public Companies and
Individual Investors